420 related articles for article (PubMed ID: 33256581)
21. Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum.
Nihashi T; Sakurai K; Kato T; Iwata K; Kimura Y; Ikenuma H; Yamaoka A; Takeda A; Arahata Y; Washimi Y; Suzuki K; Bundo M; Sakurai T; Okamura N; Yanai K; Ito K; Nakamura A;
J Alzheimers Dis; 2022; 85(1):223-234. PubMed ID: 34776443
[TBL] [Abstract][Full Text] [Related]
22. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
Malpetti M; Kievit RA; Passamonti L; Jones PS; Tsvetanov KA; Rittman T; Mak E; Nicastro N; Bevan-Jones WR; Su L; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
Brain; 2020 May; 143(5):1588-1602. PubMed ID: 32380523
[TBL] [Abstract][Full Text] [Related]
23. Magnetic resonance image-based brain age as a discriminator of dementia conversion in patients with amyloid-negative amnestic mild cognitive impairment.
Kim HW; Kim HJ; Lee H; Yang H; Rieu Z; Lee JH
Sci Rep; 2023 Dec; 13(1):22467. PubMed ID: 38105274
[TBL] [Abstract][Full Text] [Related]
24. Tau PET in Alzheimer disease and mild cognitive impairment.
Cho H; Choi JY; Hwang MS; Lee JH; Kim YJ; Lee HM; Lyoo CH; Ryu YH; Lee MS
Neurology; 2016 Jul; 87(4):375-83. PubMed ID: 27358341
[TBL] [Abstract][Full Text] [Related]
25. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
26. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease.
Marizzoni M; Ferrari C; Macis A; Jovicich J; Albani D; Babiloni C; Cavaliere L; Didic M; Forloni G; Galluzzi S; Hoffmann KT; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Pizzini F; Rossini PM; Salvatore M; Schönknecht P; Soricelli A; Del Percio C; Hensch T; Hegerl U; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
J Alzheimers Dis; 2019; 69(1):49-58. PubMed ID: 30958351
[TBL] [Abstract][Full Text] [Related]
27. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
28. Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases.
Lee SH; Cho H; Choi JY; Lee JH; Ryu YH; Lee MS; Lyoo CH
Mov Disord; 2018 Feb; 33(2):262-272. PubMed ID: 29168583
[TBL] [Abstract][Full Text] [Related]
29. White matter abnormalities and structural hippocampal disconnections in amnestic mild cognitive impairment and Alzheimer's disease.
Rowley J; Fonov V; Wu O; Eskildsen SF; Schoemaker D; Wu L; Mohades S; Shin M; Sziklas V; Cheewakriengkrai L; Shmuel A; Dagher A; Gauthier S; Rosa-Neto P;
PLoS One; 2013; 8(9):e74776. PubMed ID: 24086371
[TBL] [Abstract][Full Text] [Related]
30. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ
J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377
[TBL] [Abstract][Full Text] [Related]
31. Correlation between visual association memory test and structural changes in patients with Alzheimer's disease and amnestic mild cognitive impairment.
Huang KL; Hsiao IT; Kuo HC; Hsieh CJ; Hsieh YC; Wu YM; Wey SP; Yen TC; Lin KJ; Huang CC
J Formos Med Assoc; 2019 Sep; 118(9):1325-1332. PubMed ID: 30579663
[TBL] [Abstract][Full Text] [Related]
32. Early detection of amyloid load using
Bullich S; Roé-Vellvé N; Marquié M; Landau SM; Barthel H; Villemagne VL; Sanabria Á; Tartari JP; Sotolongo-Grau O; Doré V; Koglin N; Müller A; Perrotin A; Jovalekic A; De Santi S; Tárraga L; Stephens AW; Rowe CC; Sabri O; Seibyl JP; Boada M
Alzheimers Res Ther; 2021 Mar; 13(1):67. PubMed ID: 33773598
[TBL] [Abstract][Full Text] [Related]
33. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
34. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
Hatashita S; Wakebe D
J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
[TBL] [Abstract][Full Text] [Related]
35. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
[TBL] [Abstract][Full Text] [Related]
36. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
37. Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease.
Florek L; Tiepolt S; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Luthardt J; Sattler B; Patt M; Hoffmann KT; Villringer A; Classen J; Gertz HJ; Sabri O; Barthel H
J Alzheimers Dis; 2018; 66(3):1105-1116. PubMed ID: 30400095
[TBL] [Abstract][Full Text] [Related]
38. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
39. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.
Mattsson N; Tosun D; Insel PS; Simonson A; Jack CR; Beckett LA; Donohue M; Jagust W; Schuff N; Weiner MW;
Brain; 2014 May; 137(Pt 5):1550-61. PubMed ID: 24625697
[TBL] [Abstract][Full Text] [Related]
40. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
Yew B; Nation DA;
Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
